EFFECT OF ORAL ALENDRONATE ON BONE-MINERAL DENSITY AND THE INCIDENCE OF FRACTURES IN POSTMENOPAUSAL OSTEOPOROSIS
EFFECT OF ORAL ALENDRONATE ON BONE-MINERAL DENSITY AND THE INCIDENCE OF FRACTURES IN POSTMENOPAUSAL OSTEOPOROSIS
复制标题
DOI：
10.1056/nejm199511303332201
复制
发表时间：
1995-11-30
影响因子：
158.5
通讯作者：
KARPF, DB
中科院分区：
文献类型：
--
作者：
LIBERMAN, UA;WEISS, SR;KARPF, DB
背景绝经后骨质疏松症是一个严重的健康问题，并补充说。我们研究了口服阿仑膦酸钠（一种氨基二膦酸盐）对994名绝经后骨质疏松症妇女骨密度、骨折发生率和身高下降的影响。这些妇女接受安慰剂或阿仑膦酸钠治疗（每天5或10毫克，持续3年，或20毫克，持续2年，然后5毫克，持续1年）;所有妇女每天接受500毫克钙。双能X线骨密度仪测量骨密度。通过分析数字化X线片确定新椎体骨折的发生和椎体畸形的进展，通过连续的高度测量确定高度损失。接受阿仑膦酸钠治疗的妇女在所有骨骼部位的骨密度都有显著的、进行性的增加，而接受安慰剂治疗的妇女骨密度降低。三年后，每天服用10毫克阿仑膦酸钠的妇女和服用安慰剂的妇女之间的骨密度平均（+/-SE）差异为脊柱8.8 ± 0.4%，股骨颈5.9 ± 0.5%，转子7.8 ± 0.6%，全身2.5 ± 0.3%（P
Background. Postmenopausal osteoporosis is a serious health problem, and additMethods. We studied the effects of oral alendronate, an aminobisphosphonate, on bone mineral density and the incidence of fractures and height loss in 994 women with postmenopausal osteoporosis. The women were treated with placebo or alendronate (5 or 10 mg daily for three years, or 20 mg for two years followed by 5 mg for one year); all the women received 500 mg of calcium daily. Bone mineral density was measured by dual-energy x-ray absorptiometry. The occurrence of new vertebral fractures and the progression of vertebral deformities were determined by an analysis of digitized radiographs, and loss of height was determined by sequential height measurements.Results. The women receiving alendronate had significant, progressive increases in bone mineral density at all skeletal sites, whereas those receiving placebo had decreases in bone mineral density. At three years, the mean (+/-SE) differences in bone mineral density between the women receiving 10 mg of alendronate daily and those receiving placebo were 8.8+/-0.4 percent in the spine, 5.9+/-0.5 percent in the femoral neck, 7.8+/-0.6 percent in the trochanter, and 2.5+/-0.3 percent in the total body (P